Relationship between Mirtazapine Dose, Plasma Concentration, Response, and Side Effects in Clinical Practice

Objective: The aim of this study was to evaluate the benefit of mirtazapine plasma concentration monitoring in a typical clinical setting. Methods: The relationship between mirtazapine plasma concentration, dose, response, and side effects was studied in 65 inpatients presenting with a depressive episode according to ICD-10. Plasma concentrations, the 17-item Hamilton Depression Rating (HAMD), and the UKU side effect rating were performed weekly. A subgroup of 45 patients was evaluated for a concentration-response relationship. Results: We found a low positive correlation between plasma concentration and dose. A low negative correlation between plasma concentration and increased duration of sleep was noted in the first week of mirtazapine treatment, but not during the entire observation time. Responders to mirtazapine treatment presented with higher plasma concentrations than non-responders, revealing a threshold concentration of 30 ng/mL. Conclusion: The mirtazapine dose is a weak predictor of mirtazapine plasma concentrations. Plasma concentration measurements may therefore be useful to adjust mirtazapine doses in non-responders with plasma concentrations below 30 ng/mL. Sedative effects appear temporary and require no plasma concentration control when standard doses are administered.

References

• 1 Bremner J D. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression.  J Clin Psychiatr. 1995;  56 519-525
• 2 Bruijn J A, Moleman P, Mulder P GH, van den Broek W W, van Hulst A M, van der Mast R C. et al . A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients.  Psychopharmacology. 1996;  127 231-237
• 3 Bruijn J A, Moleman P, Mulder P GH, van den Broek W W, van Hulst A M, van den B roek. Depressed in-patients respond differently to imipramine and mirtazapine.  Pharmacopsychiatry. 1999;  32 87-92
• 4 Bühl A, Zöfel P. SPSS 11. Einführung in die moderne Datenanalyse unter Windows. Munich; Pearson Education Deutschland GmbH 2002: P. 633-639
• 5 Claghorn J L, Lesem M D. A double-blind placebo-controlled study of mirtazapine in depressed outpatients.  J Aff Disord. 1995;  34 165-171
• 6 Dahl M L, Voortman G, Alm C, Elwin C E, Delbressine L, Vos R. et al . In vitro and in vivo studies on the disposition of mirtazapine in humans.  Clin Drug Invest. 1997;  13 37-46
• 7 De Boer T, Maura G, Raiteri M, de Vos C J, Wieringa L H, Pinder R M. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, mirtazapine and its enantiomers.  Neuropharmacol. 1988;  27 399-408
• 8 Degner D, Grohmann R, Kropp S, Rüther E, Bender S, Engel R R. et al . Severe adverse drug reactions of antidepressants: Results of the German Multicenter Drug Surveillance Program AMSP.  Pharmacopsychiatry. 2004;  37 S39-45
• 9 Frahnert C, Rao M L, Grasmäder K. Determination of eighteen antidepressants, four antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring.  J Chromat B. 2003;  794 35-47
• 10 Grasmäder K, Lohmann P L, Kuss H J, Laux G, Hiemke C, Rao M L. Therapeutisches Drug-Monitoring von Antidepressiva - therapeutischer und gesundheitsökonomischer Nutzen.  Med Mo Pharm. 2003;  26 162-164
• 11 Grohmann R, Engel R R, Geissler K H, Rüther E. Psychotropic drug use in psychiatric inpatients: Recent trends and changes over time - data from the AMSP study.  Pharmacopsychiatry. 2004;  37 S 27-38
• 12 Hamilton M. A rating scale for depression.  J Neurol Neurosurg Psychiat. 1960;  23 56-62
• 13 Kasper S, Praschak-Rieder N, Tauscher J, Wolf R. A risk-benefit assessment of mirtazapine in the treatment of depression.  Drug Saf. 1997;  17 251-64
• 14 Khan M C. A randomised, double-blind, placebo-controlled, 5-weeks’ study of Org 3770 (mirtazapine) in major depression.  Hum Psychopharmacol. 1995;  10 S119-124
• 15 Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmacher T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine.  Pharmacopsychiatry. 2002;  35 220-225
• 16 Lingjaerde O, Ahlfors U G, Bech P, Dencker S J, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.  Acta Psychiatr Scand Suppl. 1987;  334 1-100
• 17 Marttila M, Jääskelainen J, Järvi R, Romanov M, Miettinen E, Sorri P. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression.  Eur Neuropsychopharmacol. 1995;  6 441-446
• 18 Mullin J, Lodge A, Bennie E, McCreadie R, Singh Batt G, Fenton G. A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression.  J Psychopharmacol. 1996;  10 235-240
• 19 Richou H, Ruimy P, Charbaut J, Delisle J P, Brunner H, Patris M. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of mirtazapine.  Hum Psychopharmacol. 1995;  10 263-271
• 20 Smith W T, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depression.  Psychopharmacol Bull. 1990;  26 191-196
• 21 Sterr A, Padberg F, Mergl R, Amann B, Mulert C, Juckel G. et al . EEG abnormalities associated with antidepressant treatment: A comparison of mirtazapine, citalopram, venlafaxine, reboxetine and amitriptyline.  Pharmacopsychiatry. 2003;  36 160
• 22 Timmer C J, Lohmann A AM, Mink C PA. Pharmacokinetic dose-proportionality study at steady-state of mirtazapine from Remeron® tablets.  Hum Psychopharmacol. 1995;  10 S97-106
• 23 Timmer C J, Sitsen J M, Delbressine L P. Clinical pharmacokinetics of mirtazapine.  Clin Pharmacokinet. 2000;  38 461-474
• 24 Vartiainen H, Leinonen E. Double-blind study of mirtazapine and placebo in hospitalized patients with major depression.  Eur Neuropsychopharmacol. 1994;  4 145-150
• 25 World Health O rganization. Tenth Revision of the International Classification of Diseases, Chapter V (F): Mental and Behavioural Disorders (including disorders of psychological development). Clinical descriptions and Diagnostic Guidelines. Bern; Verlag Hans Huber 1991
• 26 Zivkov M, de Jongh G D. Mirtazapine versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients.  Hum Psychopharmacol. 1995;  10 173-180